Producto
ER-PREDICT: A novel assay predicting disease recurrence in HR+/HER2- breast cancer
A nove multigene signature designed to identify HR+/HER2- breast cancer patients at high genomic risk of recurrence, providing a powerful tool for precise clinical decision-making.
Head of Technology Transfer Office en ISTITUTO EUROPEO DI ONCOLOGIA SRL